Identification of a novel S6K1 inhibitor, rosmarinic acid methyl ester, for treating cisplatin-resistant cervical cancer

BACKGROUND: The mTOR/S6K1 signaling pathway is often activated in cervical cancer, and thus considered a molecular target for cervical cancer therapies. Inhibiting mTOR is cytotoxic to cervical cancer cells and creates a synergistic anti-tumor effect with conventional chemotherapy agents. In this st...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:BMC Cancer
Autores principales: Nam, Ki Hong, Yi, Sang Ah, Nam, Gibeom, Noh, Jae Sung, Park, Jong Woo, Lee, Min Gyu, Park, Jee Hun, Oh, Hwamok, Lee, Jieun, Lee, Kang Ro, Park, Hyun-Ju, Lee, Jaecheol, Han, Jeung-Whan
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6683399/
https://ncbi.nlm.nih.gov/pubmed/31387554
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5997-2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares